Investors

Financials & Filings

Filing date Form Description Filing Group View
4

Statement of changes in beneficial ownership of securities

3,4,5
ARS

An annual report to security holders

Annual Filings
10-Q

Quarterly report which provides a continuing view of a company's financial position

Quarterly Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
DEF 14A

Official notification to shareholders of matters to be brought to a vote ("Proxy")

Proxy Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
10-K

Annual report which provides a comprehensive overview of the company for the past year

Annual Filings
8-K

Report of unscheduled material events or corporate event

Current Reports
4/A

Amendment to a previously filed 4

3,4,5
UPLOAD

UPLOAD

Other

Data provided by Kaleidoscope.

GNI Group, Ltd. (2160:Tokyo) (“GNI Japan”) holds an indirect, controlling interest in Gyre Therapeutics, Inc. From time to time, GNI Japan will disclose historical and forward looking information, which will include information about our business. We may not have previously disclosed such information. Please refer to https://www.gnipharma.com/ir/yuho/ for GNI Japan’s Investor Information and Securities Reports.